Generical S.A Pharmaceutical Import Profile — Dominican Republic (DGFT 2022–2026)

Name: Generical S.A Pharmaceutical Import Records from India — 2 Products, $1.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Generical S.A — Pharmaceutical Importer Profile (2026) | 2 Products, $1.4M Trade | TransData Nexus

Who Are the Verified Indian Suppliers to Generical S.A?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Medispray Laboratories Private Limited	$1.2M	43	94.2%
Cipla Limited	$73.3K	6	5.8%

Generical S.A sources from 2 verified Indian suppliers across 29 distinct formulations. The sourcing is highly concentrated — Medispray Laboratories Private Limited accounts for 94.2% of total imports, indicating a strategic single-source relationship.

What Formulations Does Generical S.A Import?

Formulation	Value	Ships
Airplus venticaps (twin Pack) with	$300.0K	6
Airplus venticaps (twin pck	$150.0K	3
Airplus venticaps(twin pck)formoterol fumarate 6mcg+budesonide 200mcg rotacaps)(19274packx1x60's=1156440 nos)(twin Pack)	$100.0K	2
Airplus venticaps(twin pck)formoterol fumarate 6mcg+budesonide 200mcg rotacaps)(19392packx1x60's=1163520 nos)(twin Pack)	$100.0K	2
Airplus venticaps(twin pck)formoterol fumarate 6mcg+budesonide 200mcg rotacaps)(19445packx1x60's=1166700 nos)(twin Pack)	$100.0K	2
Airplus venticaps(twin Pack)with	$50.0K	1

What Products Does Generical S.A Import?

Top Products by Import Value

1Formoterol$750.0K 2Budesonide$600.0K

Generical S.A Therapeutic Categories — 1 Specializations

Generical S.A imports across 1 therapeutic categories, with Respiratory (100.0%), representing the largest segments. The portfolio is concentrated — top 5 products = 100% of total imports.

Respiratory

2 products · 100.0% · $1.4M

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Formoterol	Respiratory	$750.0K	15	1.3%	11
2	Budesonide	Respiratory	$600.0K	12	0.3%	15

Key Metrics

Total Import Value$1.4M

Products2

Shipments27

Categories1

CountryDominican Republic

#1 Rankings0

Indian Suppliers2

Formulations29

Top Categories

Respiratory100.0%

Indian Suppliers

Last updated: March 28, 2026

Generical S.A — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Generical S.A. is a pharmaceutical importer based in the Dominican Republic, specializing in the acquisition of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company plays a pivotal role in the Dominican Republic's pharmaceutical distribution network, ensuring the availability of essential medications to meet the healthcare needs of the population. While specific details about its parent company are not publicly disclosed, Generical S.A. operates independently, focusing on sourcing and importing pharmaceutical products from international suppliers.

2Distribution Network

Generical S.A. maintains a centralized distribution hub in Santo Domingo, the capital city of the Dominican Republic. This strategic location enables efficient logistics and timely delivery of pharmaceutical products across the nation. The company's distribution network is designed to ensure that imported medications reach various healthcare facilities, pharmacies, and hospitals throughout the country, thereby supporting the national healthcare infrastructure.

3Industry Role

Supplier Relationship Intelligence — Generical S.A

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Generical S.A. exhibits a high degree of sourcing concentration, with a total import value of $1.4 million USD from India across 27 shipments. The company's portfolio is entirely focused on two products—Formoterol and Budesonide—imported from two suppliers: Medispray Laboratories Private Limited and Cipla Limited. This concentrated sourcing strategy may offer benefits such as streamlined logistics and potentially favorable pricing agreements. However, it also introduces risks related to supply chain disruptions, regulatory changes, or quality control issues with these suppliers. The absence of diversification in both product offerings and supplier base suggests a strategic choice to maintain simplicity and control over the supply chain, but it also highlights the need for contingency planning to mitigate potential risks.

2Supply Chain Resilience

The resilience of Generical S.A.'s supply chain is closely tied to its reliance on a limited number of suppliers and products. The company's focus on Formoterol and Budesonide, sourced exclusively from Medispray Laboratories Private Limited and Cipla Limited, respectively, means that any disruptions affecting these suppliers could significantly impact Generical S.A.'s ability to meet market demand. Additionally, the concentration of shipments from a single country—India—exposes the company to risks associated with geopolitical events, regulatory changes, or logistical challenges in that region. To enhance supply chain resilience, Generical S.A. might consider diversifying its supplier base and product portfolio, thereby reducing dependency on specific suppliers and regions.

3Strategic Implications

Generical S.A.'s concentrated sourcing strategy positions the company to negotiate favorable terms with its suppliers, potentially leading to cost advantages and streamlined operations. However, this approach also makes the company vulnerable to supply chain disruptions and market fluctuations affecting its limited product range. For Indian exporters, the current sourcing pattern indicates a stable demand for Formoterol and Budesonide in the Dominican Republic market. This presents an opportunity to strengthen relationships with Generical S.A. by ensuring consistent product quality, reliable delivery schedules, and competitive pricing. Additionally, Indian exporters could explore opportunities to introduce new products that align with Generical S.A.'s existing portfolio, thereby expanding their market presence in the Dominican Republic.

TransData Nexus Research · Verified DGFT customs dataMar 2026

Importing Pharmaceuticals into Dominican Republic — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Dominican Republic

1Regulatory Authority & Framework

The Dirección General de Medicamentos, Alimentos y Productos Sanitarios (DIGEMAPS) is the primary regulatory authority overseeing pharmaceutical imports in the Dominican Republic. Under Law No. 50-88 on Drugs and Controlled Substances, amended by Law 35-90, DIGEMAPS is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products entering the country. Pharmaceutical companies must obtain a Sanitary Register from DIGEMAPS for each product they intend to import. This registration process involves submitting comprehensive documentation, including product formulations, manufacturing processes, and clinical trial data, to demonstrate compliance with national health standards. The Sanitary Register is valid for five years and must be renewed upon expiration.

2Import Licensing & GMP

Import licensing is mandatory for pharmaceutical products entering the Dominican Republic. Companies must secure a Sanitary Register from DIGEMAPS for each product, as previously mentioned. Additionally, adherence to Good Manufacturing Practices (GMP) is a critical requirement. DIGEMAPS recognizes GMP certifications from reputable international bodies, including the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers hold valid GMP certifications from these recognized organizations to facilitate the importation process. Furthermore, wholesale distribution authorization is required to operate within the Dominican Republic, ensuring that companies comply with local regulations governing the storage, handling, and distribution of pharmaceutical products.

3Quality & Labeling

Pharmaceutical products imported into the Dominican Republic must undergo batch testing to verify their quality, safety, and efficacy. Stability studies are also required to ensure that products maintain their intended quality throughout their shelf life. Labeling must be in Spanish and include essential information such as product name, active ingredients, dosage form, strength, manufacturing details, expiration date, and storage conditions. Serialization mandates may apply to facilitate traceability and prevent counterfeit products from entering the market. Importers should consult DIGEMAPS for specific labeling and serialization requirements to ensure compliance with national regulations.

4Recent Regulatory Changes

Between 2024 and 2026, the Dominican Republic has implemented several regulatory changes affecting pharmaceutical imports. These include stricter enforcement of GMP certification requirements, updates to labeling standards to enhance consumer safety, and the introduction of electronic tracking systems for imported pharmaceutical products. Additionally, there have been revisions to the Sanitary Register application process, aiming to streamline procedures and improve efficiency. Pharmaceutical companies importing into the Dominican Republic must stay informed about these changes to ensure ongoing compliance and uninterrupted market access.

TransData Nexus Research · Dominican Republic regulatory databasesMar 2026

Seller's Guide — How to Become a Supplier to Generical S.A

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Dominican Republic market by partnering with Generical S.A. The company's established distribution network and focus on respiratory medications create a conducive environment for introducing additional products within this therapeutic area. Potential gaps in Generical S.A.'s current sourcing include the need for alternative suppliers to mitigate risks associated with supplier concentration and the introduction of new formulations to meet evolving patient needs. Indian exporters can leverage these opportunities by ensuring compliance with Dominican regulatory standards and offering competitive pricing and reliable delivery schedules.

2Requirements & Qualifications

Indian exporters seeking to supply Generical S.A. and the broader Dominican Republic market must ensure that their products are registered with DIGEMAPS and comply with local GMP standards. Obtaining GMP certifications from recognized international bodies such as WHO and PIC/S is essential. Additionally, products must meet labeling requirements, including Spanish language labeling and adherence to serialization mandates. Exporters should also be prepared to provide comprehensive documentation, including product formulations, manufacturing processes, and clinical trial data, to facilitate the Sanitary Register application process.

3How to Approach

To establish a partnership with Generical S.A., Indian exporters should initiate contact by providing detailed product information, including compliance with Dominican regulatory standards. Participating in tenders and responding to requests for proposals can enhance visibility and demonstrate commitment to the Dominican market. Developing a clear regulatory filing strategy, including timelines for obtaining necessary approvals, is crucial. Building a relationship with Generical S.A. through transparent communication and consistent product quality will be key to a successful partnership.

TransData Nexus Research · Industry procurement practicesMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Buyer Matching: Generical S.A identified across shipments using consignee name normalization.
2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
3.Market Share: Calculated per product as Generical S.A's capped value divided by total Indian exports for that product.
4.Shipment Count: Based on 27 individual customs records matching Generical S.A.
5.Supplier Verification: Generical S.A sources from 2 verified Indian suppliers across 29 formulations, confirmed from customs records.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

2 Products Tracked

1 therapeutic categories

Expert-Reviewed

By pharmaceutical trade specialists

Generical S.A

Generical S.A — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Generical S.A?

What Formulations Does Generical S.A Import?

What Products Does Generical S.A Import?

Top Products by Import Value

Generical S.A Therapeutic Categories — 1 Specializations

Import Portfolio — Top 2 by Import Value

Key Metrics

Top Categories

Indian Suppliers

Generical S.A — Corporate Profile & Information

1Company Overview

2Distribution Network

3Industry Role

Related Trade Data

Need Detailed Data?

Supplier Relationship Intelligence — Generical S.A

1Sourcing Concentration Analysis

2Supply Chain Resilience

3Strategic Implications

Importing Pharmaceuticals into Dominican Republic — Regulatory Framework

1Regulatory Authority & Framework

2Import Licensing & GMP

3Quality & Labeling

4Recent Regulatory Changes

Generical S.A — Procurement Pattern Analysis

1Product Strategy

2Sourcing Profile

3Market Positioning

Seller's Guide — How to Become a Supplier to Generical S.A

1Opportunity Assessment

2Requirements & Qualifications

3How to Approach

Frequently Asked Questions — Generical S.A

What products does Generical S.A import from India?

Who supplies pharmaceuticals to Generical S.A from India?

What is Generical S.A's total pharmaceutical import value?

What therapeutic categories does Generical S.A focus on?

Get Full Generical S.A Import Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Data Source & Methodology